Interestingly, tumor PD-L1 expression alone was not predictive of efficacy outcomes, and no significant relationship between PD-L1 expression and improvement in progression-free survival (PFS) in patients receiving combined immunotherapy was found. This evidence concerns the gene CD274 and neoplasm.